Sept. 9, 2021, 4:38 PM
Allergan PLC investors who say the company misled them about breast implant safety may pursue their securities suit as a group after a federal judge in New York certified their class.
Investors accuse the pharmaceutical company of downplaying the strength of a link between its implant products and cancer ahead of a European recall. They’re entitled to a presumption that members of the now-certified class relied on the company’s statements when they acquired its securities, the U.S. District Court for the Southern District of New York said.
Allergan conceded that the pension fund serving as lead plaintiff—picked in …